Significant increase of succinylacetone within the first 12 h of life in hereditary tyrosinemia type 1

European Journal of Pediatrics

Volumn 169, Issue 5, 2010, Pages 569-572

  Schlump, Jan Ulrich ^a   Mayatepek, Ertan ^a   Spiekerkoetter, Ute ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

HT1; Newborn screening; Nitisinone

Indexed keywords

ALPHA FETOPROTEIN; FUMARYLACETOACETASE; NITISINONE; SUCCINYLACETONE; TYROSINE;

ARTICLE; CASE REPORT; CESAREAN SECTION; CHORION VILLUS SAMPLING; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; ISOTOPE DILUTION ASSAY; NEWBORN; NEWBORN SCREENING; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN RESTRICTION; TYROSINEMIA;

AGE FACTORS; ALPHA-FETOPROTEINS; FEMALE; FETAL BLOOD; HEPTANOATES; HUMANS; INFANT, NEWBORN; PRENATAL DIAGNOSIS; TYROSINEMIAS;

EID: 77952095448     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-009-1074-1     Document Type: Article

References (24)

1. OY Al-Dirbashi MS Rashed M Jacob, et al. 2008 Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS Biomed Chromatogr 22 1181 1185 10.1002/bmc.1049 1:CAS:528:DC%2BD1cXhsVOjtb7L 18651606
2. P Allard A Grenier MS Korson TH Zytkovicz 2004 Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots Clin Biochem 37 1010 1015 10.1016/j. clinbiochem.2004.07.006 1:CAS:528:DC%2BD2cXovV2gs7s%3D 15498530 (Pubitemid 39388663)
3. F Alvarez, et al. 2005 Nitisinone (NTBC) treatment of hepatorenal tyrosinemia in Quebec J Inherit Metab Dis 28 Suppl 1 49
4. M Grompe 2001 The pathophysiology and treatment of hereditary tyrosinemia type 1 Semin Liver Dis 21 563 571 10.1055/s-2001-19035 1:CAS:528: DC%2BD38XislCjsQ%3D%3D 11745044 (Pubitemid 33131048)
5. E Holme S Lindstedt 1998 Tyrosinaemia type I and NTBC (2-(2-nitro-4- trifluoromethylbenzoyl)-1, 3-cyclohexanedione) J Inherit Metab Dis 21 507 517 10.1023/A:1005410820201 1:CAS:528:DyaK1cXlslyksrs%3D 9728331 (Pubitemid 28391503)
6. E Holme S Lindstedt 2000 Nontransplant treatment of tyrosinemia Clin Liver Dis 4 805 814 10.1016/S1089-3261(05)70142-2 1:STN:280: DC%2BD3MzgtV2rsQ%3D%3D 11232358
7. MK Hostetter HL Levy HS Winter GJ Knight JE Haddow 1983 Evidence for liver disease preceding amino acid abnormalities in hereditary tyrosinemia N Engl J Med 308 1265 1267 1:STN:280:DyaL3s7pt1ehtQ%3D%3D 6188953
8. CJ Koelink P van Hasselt A van der Ploeg, et al. 2006 Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer? Mol Genet Metab 89 4 310 315 10.1016/j.ymgme.2006.07.009 1:CAS:528:DC%2BD28Xht1SgsL%2FN 17008115 (Pubitemid 44692538)
9. G la Marca S Malvagia E Zammarchi, et al. 2008 The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs Rapid Commun Mass Spectrom 22 812 818 10.1002/rcm.3428 18278819 (Pubitemid 351442555)
10. B Lindblad S Lindstedt G Steen 1974 On the enzymatic defects in hereditary tyrosinemia Proc Natl Acad Sci 74 4641 4645 10.1073/pnas.74.10.4641
11. S Lindstedt E Holme EA Lock O Hjalmarson, et al. 1992 Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase Lancet 340 813 817 10.1016/0140-6736(92)92685-9 1:STN:280: DyaK3s%2FitlWlsw%3D%3D 1383656
12. MJ Magera N Gunawardena D Matern, et al. 2006 Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I Mol Genet Metab 88 16 21 10.1016/j.ymgme.2005.12.005 1:CAS:528: DC%2BD28XjvVGgtr4%3D 16448836
13. Mitchell G, Grompe M, Lambert M, Tanguay R (2001) Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 1777-1806
14. MS Rashed LY Al-Ahaidib OY Al-Dirbashi, et al. 2005 Tandem mass spectrometric assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia Anal Biochem 339 310 317 10.1016/j.ab.2005.01.014 1:CAS:528:DC%2BD2MXis1Gktr0%3D 15797572 (Pubitemid 40395289)
15. P Russo G Mitchell R Tanguay 2001 Tyrosinemia: a review Pediatr Dev Pathol 4 212 221 10.1007/s100240010146 1:CAS:528:DC%2BD3MXktVGrtbw%3D 11370259 (Pubitemid 32423820)
16. J Sander N Janzen M Peter, et al. 2006 Newborn screening for hepatorenal tyrosinemia: tandem mass spectrometric quantification of succinylacetone Clin Chem 52 482 487 10.1373/clinchem.2005.059790 1:CAS:528:DC%2BD28Xit1ShtLg%3D 16439608
17. S Santra U Baumann 2008 Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1 Expert Opin Pharmacother. 9 1229 1236 10.1517/14656566.9.7.1229 1:CAS:528:DC%2BD1cXkvVemsbg%3D 18422479 (Pubitemid 351721759)
18. A Schulze D Frommhold GF Hoffmann E Mayatepek 2001 Spectrophotometric microassay for delta-aminolevulinate dehydratase in dried-blood spots as confirmation for hereditary tyrosinemia type I Clin Chem 47 1424 1429 1:CAS:528:DC%2BD3MXls1Squrs%3D 11468232
19. CR Scott 2006 The genetic tyrosinemias Am J Med Genet Part C Semin Med Genet 142C 121 126 10.1002/ajmg.c.30092 1:CAS:528:DC%2BD2sXms1Wisbw%3D 16602095
20. BA Tarini 2007 The current revolution in newborn screening: new technology, old controversies Arch Pediatr Adolesc Med 161 767 772 10.1001/archpedi.161.8.767 17679658 (Pubitemid 47236446)
21. C Turgeon MJ Magera P Allard, et al. 2008 Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots Clin Chem 54 657 664 10.1373/clinchem.2007.101949 1:CAS:528:DC%2BD1cXkt1equrk%3D 18281422 (Pubitemid 351573716)
22. M Wästfeld B Fadeel JI Henter 2006 A journey of hope: lessons learned from studies on rare diseases and orphan drugs J Intern Med 260 1 10 10.1111/j.1365-2796.2006.01666.x (Pubitemid 43894064)
23. JF Weigel N Janzen RW Pfäffle, et al. 2007 Tandem mass spectrometric determination of succinylacetone in dried blood spots enables presymptomatic detection in a case of hepatorenal tyrosinaemia J Inherit Metab Dis 30 610 10.1007/s10545-007-0608-9 1:CAS:528:DC%2BD2sXhtVSisL3O 17694358
24. Wilson JM, Jungner G (1968) Principles and practice of screening for disease. WHO, Geneva, p 343